Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa
Identifieur interne : 006569 ( Main/Merge ); précédent : 006568; suivant : 006570Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa
Auteurs : Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-11.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Callithrix, Disease Models, Animal, Dose-Response Relationship, Drug, Dyskinesia, Drug-Induced (physiopathology), Female, Levodopa (toxicity), L‐dopa, MPTP, Male, Motor Activity (drug effects), Motor Skills (drug effects), Neurologic Examination (drug effects), Parkinson's disease, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (physiopathology), Recurrence, dyskinesia, motor complication.
- MESH :
- chemical , toxicity : Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinsonian Disorders.
- drug effects : Motor Activity, Motor Skills, Neurologic Examination.
- physiopathology : Dyskinesia, Drug-Induced, Parkinsonian Disorders.
- Animals, Callithrix, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Male, Recurrence.
Abstract
A wide range of motor fluctuations develop in Parkinson's disease (PD) patients after prolonged levodopa (L‐dopa) treatment, but few experimental models exist in which these can be investigated. We report on motor fluctuations occurring in MPTP‐treated common marmosets (Callithrix jacchus) treated repeatedly with L‐dopa. All animals showed an improvement in motor function in response to L‐dopa, and rapidly developed peak‐dose dyskinesia. During the period of L‐dopa action, brief periods of immobility were occasionally observed. After acute L‐dopa challenge, animals exhibited a worsening of motor function before improvement, and after the beneficial response to L‐dopa declined, motor performance showed rebound worsening to below‐baseline values. Before L‐dopa challenge and during wearing‐off and rebound worsening, leg dystonias were observed. Although these findings cannot necessarily be generalized to all MPTP‐treated nonhuman primates, they demonstrate that MPTP‐treated marmosets show a range of different motor fluctuations analogous to those seen in PD patients chronically treated with L‐dopa. Therefore, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates can provide a model in which the pathophysiology of treatment complications can be investigated. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10263
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C15
- to stream Istex, to step Curation: 001C15
- to stream Istex, to step Checkpoint: 002E55
- to stream PubMed, to step Corpus: 003905
- to stream PubMed, to step Curation: 003905
- to stream PubMed, to step Checkpoint: 003B85
- to stream Ncbi, to step Merge: 000946
- to stream Ncbi, to step Curation: 000946
- to stream Ncbi, to step Checkpoint: 000946
Links to Exploration step
ISTEX:7AE239A5056FCFE0C0C771254291F411A50DE157Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa</title><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name></author><author><name sortKey="Al Arghouthy, Ghassan" sort="Al Arghouthy, Ghassan" uniqKey="Al Arghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name></author><author><name sortKey="Jackson, Michael" sort="Jackson, Michael" uniqKey="Jackson M" first="Michael" last="Jackson">Michael Jackson</name></author><author><name sortKey="Smith, Lance" sort="Smith, Lance" uniqKey="Smith L" first="Lance" last="Smith">Lance Smith</name></author><author><name sortKey="Zeng, Bai Un" sort="Zeng, Bai Un" uniqKey="Zeng B" first="Bai-Yun" last="Zeng">Bai-Yun Zeng</name></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7AE239A5056FCFE0C0C771254291F411A50DE157</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10263</idno><idno type="url">https://api.istex.fr/document/7AE239A5056FCFE0C0C771254291F411A50DE157/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C15</idno><idno type="wicri:Area/Istex/Curation">001C15</idno><idno type="wicri:Area/Istex/Checkpoint">002E55</idno><idno type="wicri:doubleKey">0885-3185:2002:Kuoppam Ki M:beginning:of:dose</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12465074</idno><idno type="wicri:Area/PubMed/Corpus">003905</idno><idno type="wicri:Area/PubMed/Curation">003905</idno><idno type="wicri:Area/PubMed/Checkpoint">003B85</idno><idno type="wicri:Area/Ncbi/Merge">000946</idno><idno type="wicri:Area/Ncbi/Curation">000946</idno><idno type="wicri:Area/Ncbi/Checkpoint">000946</idno><idno type="wicri:doubleKey">0885-3185:2002:Kuoppam Ki M:beginning:of:dose</idno><idno type="wicri:Area/Main/Merge">006569</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa</title><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Al Arghouthy, Ghassan" sort="Al Arghouthy, Ghassan" uniqKey="Al Arghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael" sort="Jackson, Michael" uniqKey="Jackson M" first="Michael" last="Jackson">Michael Jackson</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Smith, Lance" sort="Smith, Lance" uniqKey="Smith L" first="Lance" last="Smith">Lance Smith</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zeng, Bai Un" sort="Zeng, Bai Un" uniqKey="Zeng B" first="Bai-Yun" last="Zeng">Bai-Yun Zeng</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1312">1312</biblScope><biblScope unit="page" to="1317">1317</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7AE239A5056FCFE0C0C771254291F411A50DE157</idno><idno type="DOI">10.1002/mds.10263</idno><idno type="ArticleID">MDS10263</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Female</term><term>Levodopa (toxicity)</term><term>L‐dopa</term><term>MPTP</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Motor Skills (drug effects)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Recurrence</term><term>dyskinesia</term><term>motor complication</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Male</term><term>Recurrence</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A wide range of motor fluctuations develop in Parkinson's disease (PD) patients after prolonged levodopa (L‐dopa) treatment, but few experimental models exist in which these can be investigated. We report on motor fluctuations occurring in MPTP‐treated common marmosets (Callithrix jacchus) treated repeatedly with L‐dopa. All animals showed an improvement in motor function in response to L‐dopa, and rapidly developed peak‐dose dyskinesia. During the period of L‐dopa action, brief periods of immobility were occasionally observed. After acute L‐dopa challenge, animals exhibited a worsening of motor function before improvement, and after the beneficial response to L‐dopa declined, motor performance showed rebound worsening to below‐baseline values. Before L‐dopa challenge and during wearing‐off and rebound worsening, leg dystonias were observed. Although these findings cannot necessarily be generalized to all MPTP‐treated nonhuman primates, they demonstrate that MPTP‐treated marmosets show a range of different motor fluctuations analogous to those seen in PD patients chronically treated with L‐dopa. Therefore, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates can provide a model in which the pathophysiology of treatment complications can be investigated. © 2002 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.10263"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa</title><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name></author><author><name sortKey="Al Arghouthy, Ghassan" sort="Al Arghouthy, Ghassan" uniqKey="Al Arghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name></author><author><name sortKey="Jackson, Michael" sort="Jackson, Michael" uniqKey="Jackson M" first="Michael" last="Jackson">Michael Jackson</name></author><author><name sortKey="Smith, Lance" sort="Smith, Lance" uniqKey="Smith L" first="Lance" last="Smith">Lance Smith</name></author><author><name sortKey="Zeng, Bai Un" sort="Zeng, Bai Un" uniqKey="Zeng B" first="Bai-Yun" last="Zeng">Bai-Yun Zeng</name></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7AE239A5056FCFE0C0C771254291F411A50DE157</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10263</idno><idno type="url">https://api.istex.fr/document/7AE239A5056FCFE0C0C771254291F411A50DE157/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C15</idno><idno type="wicri:Area/Istex/Curation">001C15</idno><idno type="wicri:Area/Istex/Checkpoint">002E55</idno><idno type="wicri:doubleKey">0885-3185:2002:Kuoppam Ki M:beginning:of:dose</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa</title><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Al Arghouthy, Ghassan" sort="Al Arghouthy, Ghassan" uniqKey="Al Arghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael" sort="Jackson, Michael" uniqKey="Jackson M" first="Michael" last="Jackson">Michael Jackson</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Smith, Lance" sort="Smith, Lance" uniqKey="Smith L" first="Lance" last="Smith">Lance Smith</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zeng, Bai Un" sort="Zeng, Bai Un" uniqKey="Zeng B" first="Bai-Yun" last="Zeng">Bai-Yun Zeng</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-11">2002-11</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1312">1312</biblScope><biblScope unit="page" to="1317">1317</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7AE239A5056FCFE0C0C771254291F411A50DE157</idno><idno type="DOI">10.1002/mds.10263</idno><idno type="ArticleID">MDS10263</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>MPTP</term><term>Parkinson's disease</term><term>dyskinesia</term><term>motor complication</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A wide range of motor fluctuations develop in Parkinson's disease (PD) patients after prolonged levodopa (L‐dopa) treatment, but few experimental models exist in which these can be investigated. We report on motor fluctuations occurring in MPTP‐treated common marmosets (Callithrix jacchus) treated repeatedly with L‐dopa. All animals showed an improvement in motor function in response to L‐dopa, and rapidly developed peak‐dose dyskinesia. During the period of L‐dopa action, brief periods of immobility were occasionally observed. After acute L‐dopa challenge, animals exhibited a worsening of motor function before improvement, and after the beneficial response to L‐dopa declined, motor performance showed rebound worsening to below‐baseline values. Before L‐dopa challenge and during wearing‐off and rebound worsening, leg dystonias were observed. Although these findings cannot necessarily be generalized to all MPTP‐treated nonhuman primates, they demonstrate that MPTP‐treated marmosets show a range of different motor fluctuations analogous to those seen in PD patients chronically treated with L‐dopa. Therefore, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates can provide a model in which the pathophysiology of treatment complications can be investigated. © 2002 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.</title><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name><affiliation wicri:level="3"><nlm:affiliation>Neurodegenerative Diseases Research Centre, King's College, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Al Barghouthy, Ghassan" sort="Al Barghouthy, Ghassan" uniqKey="Al Barghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name></author><author><name sortKey="Jackson, Michael" sort="Jackson, Michael" uniqKey="Jackson M" first="Michael" last="Jackson">Michael Jackson</name></author><author><name sortKey="Smith, Lance" sort="Smith, Lance" uniqKey="Smith L" first="Lance" last="Smith">Lance Smith</name></author><author><name sortKey="Zeng, Bai Yun" sort="Zeng, Bai Yun" uniqKey="Zeng B" first="Bai-Yun" last="Zeng">Bai-Yun Zeng</name></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12465074</idno><idno type="pmid">12465074</idno><idno type="doi">10.1002/mds.10263</idno><idno type="wicri:Area/PubMed/Corpus">003905</idno><idno type="wicri:Area/PubMed/Curation">003905</idno><idno type="wicri:Area/PubMed/Checkpoint">003B85</idno><idno type="wicri:Area/Ncbi/Merge">000946</idno><idno type="wicri:Area/Ncbi/Curation">000946</idno><idno type="wicri:Area/Ncbi/Checkpoint">000946</idno><idno type="wicri:doubleKey">0885-3185:2002:Kuoppam Ki M:beginning:of:dose</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.</title><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name><affiliation wicri:level="3"><nlm:affiliation>Neurodegenerative Diseases Research Centre, King's College, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Al Barghouthy, Ghassan" sort="Al Barghouthy, Ghassan" uniqKey="Al Barghouthy G" first="Ghassan" last="Al-Barghouthy">Ghassan Al-Barghouthy</name></author><author><name sortKey="Jackson, Michael" sort="Jackson, Michael" uniqKey="Jackson M" first="Michael" last="Jackson">Michael Jackson</name></author><author><name sortKey="Smith, Lance" sort="Smith, Lance" uniqKey="Smith L" first="Lance" last="Smith">Lance Smith</name></author><author><name sortKey="Zeng, Bai Yun" sort="Zeng, Bai Yun" uniqKey="Zeng B" first="Bai-Yun" last="Zeng">Bai-Yun Zeng</name></author><author><name sortKey="Quinn, Niall" sort="Quinn, Niall" uniqKey="Quinn N" first="Niall" last="Quinn">Niall Quinn</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Female</term><term>Levodopa (toxicity)</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Motor Skills (drug effects)</term><term>Neurologic Examination (drug effects)</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Recurrence</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Male</term><term>Recurrence</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A wide range of motor fluctuations develop in Parkinson's disease (PD) patients after prolonged levodopa (L-dopa) treatment, but few experimental models exist in which these can be investigated. We report on motor fluctuations occurring in MPTP-treated common marmosets (Callithrix jacchus) treated repeatedly with L-dopa. All animals showed an improvement in motor function in response to L-dopa, and rapidly developed peak-dose dyskinesia. During the period of L-dopa action, brief periods of immobility were occasionally observed. After acute L-dopa challenge, animals exhibited a worsening of motor function before improvement, and after the beneficial response to L-dopa declined, motor performance showed rebound worsening to below-baseline values. Before L-dopa challenge and during wearing-off and rebound worsening, leg dystonias were observed. Although these findings cannot necessarily be generalized to all MPTP-treated nonhuman primates, they demonstrate that MPTP-treated marmosets show a range of different motor fluctuations analogous to those seen in PD patients chronically treated with L-dopa. Therefore, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates can provide a model in which the pathophysiology of treatment complications can be investigated.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006569 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 006569 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:7AE239A5056FCFE0C0C771254291F411A50DE157
|texte= Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa
}}
| This area was generated with Dilib version V0.6.23. |  |